Skip to content

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07592806
Acronym
CRISTEL
Enrollment
2000
Registered
2026-05-18
Start date
2026-09-01
Completion date
2036-09-01
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Operation With Transplant of Whole Organ

Brief summary

The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Detailed description

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1). Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe. Among the unknowns that remain despite these registry data, the following should be noted: Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception); Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting; Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2); The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler; The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4); Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ? Infant morbidity in the short and medium term. To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination). The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

Interventions

OTHERBlood sample

Two optional (non-mandatory) biological samples may be collected as part of this study: A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected. A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function).

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
No

Inclusion criteria

* Female patient aged 18 years or older and of childbearing age * Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney) * Has a positive blood beta-hCG test result \> 5 IU/L ("positive") * Has signed an informed consent form * Affiliated with a health insurance plan

Exclusion criteria

* Patient deprived of liberty or under legal guardianship * Patient refuses to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).Annually over the 10-year study periodThe primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).

Secondary

MeasureTime frameDescription
Birth weight of the newborn (in grams)day of deliveryBirth weight of the newborn (in grams)
Rate of spontaneous miscarriageThrough study completion, an average of 1 yearRate of spontaneous miscarriage
Rate of cesarean sectionThrough study completion, an average of 1 yearRate of cesarean section
Rate of prematurityThrough study completion, an average of 1 yearRate of prematurity
Rate of intrauterine growth restrictionThrough study completion, an average of 1 yearRate of intrauterine growth restriction
the duration of hospital stay for both the mother and the newbornThrough study completion, an average of 1 yearthe duration of hospital stay for both the mother and the newborn
incidence of biopsy-proven acute rejection up to 12 months postpartum;up to 12 months postpartum;incidence of biopsy-proven acute rejection up to 12 months postpartum;
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.3 months and 12 months postoartumincidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
Trajectory of proteinuria (protein-to-creatinine ratio)During pregnancy (up to 40 weeks if gestation)Trajectory of proteinuria (protein-to-creatinine ratio)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,During pregnancy (up to 40 weeks if gestation)Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
Trajectory of anti-angiogenic factors during pregnancyDuring pregnancy (up to 40 weeks if gestation)Trajectory of anti-angiogenic factors during pregnancy
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birthRate of maternal hospitalizations before delivery and in the postpartum period
Apgar scoreday of deliveryApgar score
Proportion of growth-restrictedday of delivery and up 3 month postpartumProportion of growth-restricted
Incidence of neonatal complications before the third month of lifeday of delivery and up 3 month postpartumIncidence of neonatal complications before the third month of life
Rate of preeclampsiaThrough study completion, an average of 1 yearRate of preeclampsia
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);3 months and 12 months postopartumTrajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
Live birth rate among transplanted mothers from the onset of pregnancy.through study completion, an average of 1 yearLive birth rate among transplanted mothers from the onset of pregnancy.
Trajectory of serum creatinine levelsDuring pregnancy (up to 40 weeks if gestation)Trajectory of serum creatinine levels
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.Day of delivery: Perioperative/PeriproceduralMode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birthRate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)

Contacts

CONTACTSahar Pr SELLAMI JALLOULI, PhD
s.sellami-jallouli@hopital-foch.com01 46 25 31 37
PRINCIPAL_INVESTIGATORAlexandre Pr Hertig, MED

Foch Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026